Caris Life Sciences Gains MolDX Approval for ChromoSeq
IRVING, Texas – May 4, 2026 Caris Life Sciences has secured MolDX approval for its flagship Caris ChromoSeq™ assay,...
AML
Advertisement
Kyowa Kirin, Kura Oncology Launch Ziftomenib AML Trial
TOKYO & SAN DIEGO, April 24, 2026 Kyowa Kirin and Kura Oncology have announced a major clinical milestone with...
PureTech Reports Positive LYT-200 Phase 1b Trial Data
BOSTON, USA, April 22, 2026 PureTech Health plc has announced positive topline results from its Phase 1b clinical trial...
CU Anschutz Secures FDA IND for CAR T-Cell Therapy
AURORA, Colo., April 2, 2026 The University of Colorado Anschutz Medical Campus Gates Institute announced it has received U.S....
AI-NGS Test Detects AML, MDS Relapse Post-Transplant
BRISBANE, Calif., Feb. 12, 2026 — CareDx announced pivotal clinical validation results for AlloHeme, the first AI-powered, next-generation sequencing...
Advertisements
Five-Year REZLIDHIA Data Reinforces Long-Term AML Outcomes
Dateline IntroductionNovember 18, 2025 — South San Francisco, CA — Rigel Pharmaceuticals has published final five-year clinical data on...
Editas Medicine Advances Gene-Editing Therapy EDIT-401
Cambridge, Massachusetts – September 2, 2025 Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene-editing biotechnology company, has nominated EDIT-401,...
Sumitomo Pharma Unveils Promising Data in Blood Cancers
Marlborough, Massachusetts – November 3, 2025 Sumitomo Pharma America, Inc. (SMPA) announced compelling new investigational data from multiple clinical...
BioNTech Advances Oncology Pipeline and Strengthens 2025 Financial Outlook
MAINZ, Germany, November 3, 2025 — BioNTech SE (Nasdaq: BNTX) reported its third quarter 2025 financial results, highlighting significant...
Aptose to Present Promising Tuspetinib AML Data at 2025 ASH Meeting
SAN DIEGO and TORONTO, November 3, 2025 — Aptose Biosciences Inc. (TSX: APS), a clinical-stage precision oncology company, announced...
Advertisement
